IP Library Granted Patent US 12,186,557
Granted Patent B2
US 12,186,557 · App. 17/805,220 · Granted Jan 7, 2025

Auricular nerve stimulation to address patient disorders, and associated systems and methods

Inventors: Vivek K. Sharma (San Ramon, CA); Konstantinos Alataris (Menlo Park, CA); Gary Heit (La Honda, CA); Jason Sutor (Pacific Grove, CA); Pankaj Sunkeri (Belmont, CA)
Assignee: NextSense, Inc.
A61N1/36034A61N1/0456A61N1/36021A61N1/36025A61N1/36036
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,186,557
App. No.
17/805,220
Granted
Jan 7, 2025
Kind
B2
Abstract

Auricular nerve stimulation techniques for addressing patient disorders, and associated systems and methods. A representative system includes a signal generator having instructions to generate an electrical therapy signal, at least a portion of the electrical therapy signal having a frequency at or above the patient's auditory frequency limit, an amplitude in an amplitude range from about 0.1 mA to about 10 mA, and a pulse width in a pulse width range from 5 microseconds to 30 microseconds. The system further includes at least one earpiece having a contoured outer surface shaped to fit against the skin of the patient's external ear, external ear canal, or both, the at least one earpiece carrying at least two transcutaneous electrodes positioned to be in electrical communication with the auricular innervation of the patient, e.g., the auricular vagal nerve.

Claims (39)

1. A system for delivering electrical signals to a person having a disorder, comprising:

a signal generator having instructions to generate an electrical signal to address the person's disorder, the disorder including at least one of asthma, allergic rhinitis, allergic bronchitis, and exercise-induced bronchoconstriction;

wherein at least a portion of the electrical signal has:

a frequency in a frequency range from about 15 kHz to about 50 kHz;

an amplitude in an amplitude range from about 0.1 mA to about 10 mA; and

a pulse width in a pulse width range from about 5 microseconds to about 30 microseconds; and

an earpiece shaped to fit against skin of the person's external ear, external ear canal, or both, the earpiece carrying an electrode coupled to the signal generator and configured to be positioned in electrical communication with at least one auricular nerve of the person,

wherein the signal generator has instructions to apply a first electrical signal to the right ear and a second electrical signal to the left ear, the second electrical signal differing from the first electrical signal with respect to one or more of frequency or amplitude.

2. The system of claim 1 , wherein the earpiece is a first earpiece shaped to fit the person's right ear, the system further comprising a second earpiece shaped to the person's left ear.

3. The system of claim 2 , wherein the signal generator has instructions to apply the first electrical signal to the first earpiece and the second electrical signal to the second earpiece (i) simultaneously, (ii) sequentially, or (iii) simultaneously during a first period, and sequentially during a second period.

4. The system of claim 1 , wherein the signal generator includes a neckpiece positionable around the person's neck, and wherein the system further comprises an earpiece link coupled between the neckpiece and the earpiece.

5. The system of claim 1 , wherein the electrical signal is one or both of a non-paresthesia-generating electrical signal and a non-sensory response electrical signal.

6. The system of claim 1 , wherein the electrode includes a conductive polymer outer surface.

7. The system of claim 6 , wherein the conductive polymer outer surface is coupled to a non-conductive backing.

8. The system of claim 1 , further comprising an external controller configured to be in wireless communication with the signal generator, wherein the external controller includes a mobile device having an application for controlling the signal generator.

9. The system of claim 1 , further comprising a feedback device configured to provide a feedback signal to the person.

10. The system of claim 9 , wherein the feedback device includes an audible feedback device configured to generate a feedback signal in the patient's audible frequency range.

11. The system of claim 10 , wherein a frequency of the feedback signal is patient-specific.

12. The system of claim 1 , further comprising a proximity sensor positioned to detect a location of the electrode relative to the patient's skin.

13. The system of claim 1 , wherein the pulse width is in a pulse width range from about 16 microseconds to about 24 microseconds.

14. The system of claim 13 , wherein the pulse width is about 20 microseconds.

15. The system of claim 1 , wherein at least a portion of the electrical signal has an interpulse period in an interpulse period range from about 1 microsecond to about 15 microseconds.

16. The system of claim 1 , wherein at least a portion of the electrical signal has an interphase period in an interphase period range from about 1 microsecond to about 10 microseconds.

17. A method for treating a person having a disorder, the disorder including at least one of: asthma, allergic rhinitis, allergic bronchitis, and exercise-induced bronchoconstriction, the method comprising:

programming a signal generator to apply an electrical signal to an auricular nerve of the person to address the person's disorder, wherein the electrical signal is applied via a plurality of transcutaneous electrodes carried by an earpiece positioned against skin of the person's external ear, external ear canal, or both;

wherein programming the signal generator to apply the first electrical signal to the patient's right ear, and programming the signal generator to apply a second electrical signal to the patient's left ear,

wherein the second electrical signal differs from the first electrical signal with respect to one or more of frequency or amplitude;

wherein at least a portion of the electrical signal has:

a frequency in a frequency range from about 15 kHz to about 50 kHz;

an amplitude in an amplitude range from about 0.1 mA to about 10 mA; and

a pulse width in a pulse width range from about 5 microseconds to about 30 microseconds.

18. The method of claim 17 , wherein programming the signal generator to apply the electrical signal includes programming the signal generator to apply one or both of a paresthesia-free electrical signal and a non-sensory-response electrical signal.

19. The method of claim 17 , wherein programming the signal generator to apply the electrical signal includes programming the signal generator to apply the electrical signal to thereby cause an auricular branch of the person's vagal nerve to generate an afferent response.

20. The method of claim 17 , wherein programming the signal generator to apply the electrical signal includes programming the signal generator to apply the electrical signal to one of the person's ears.

21. The method of claim 17 , wherein programming the signal generator to apply the electrical signal includes programming the signal generator to apply the electrical signal to both of the person's ears.

22. The method of claim 17 , wherein programming the signal generator includes programming the signal generator to increase the amplitude of the electrical signal over multiple steps from a first value to a second value.

23. The method of claim 17 , wherein programming the signal generator to apply the electrical signal includes programming the signal generator to apply the electrical signal for a duration of from about two seconds to about thirty minutes.

24. The method of claim 17 , wherein programming the signal generator to apply the electrical signal includes programming the signal generator to apply the electrical signal over the course of at most two session per day.

25. The method of claim 17 , wherein programming the signal generator to apply the electrical signal includes programming the signal generator to apply the electrical signal at a frequency above the person's auditory threshold.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2022
From: NESOS CORP.
To: NESOS LLC
Reel/Frame 061226/0120 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2022
From: NESOS LLC
To: NEXTSENSE, INC.
Reel/Frame 061226/0401 →
Continuity (6)
Continuation 17066404 · Oct 8, 2020
Division 16581139 · Sep 24, 2019
Provisional Application 62891203 · Aug 23, 2019
Provisional Application 62785205 · Dec 26, 2018
Provisional Application 62735492 · Sep 24, 2018
Related Publication 20230145581A1 · May 11, 2023
References Cited (168)
US 4702254A · Zabara · 1987 [cited by applicant]
US 4867164A · Zabara · 1989 [cited by applicant]
US 5025807A · Zabara · 1991 [cited by applicant]
US 5215086A · Terry, Jr. et al. · 1993 [cited by applicant]
US 5231988A · Wernicke et al. · 1993 [cited by applicant]
US 5263480A · Wernicke et al. · 1993 [cited by applicant]
US 5269303A · Wernicke et al. · 1993 [cited by applicant]
US 5299569A · Wernicke et al. · 1994 [cited by applicant]
US 5330515A · Rutecki et al. · 1994 [cited by applicant]
US 5335657A · Terry, Jr. et al. · 1994 [cited by applicant]
US 5458625A · Kendall · 1995 [cited by applicant]
US 5540730A · Terry, Jr. et al. · 1996 [cited by applicant]
US 5707400A · Terry, Jr. et al. · 1998 [cited by applicant]
US 5713923A · Ward et al. · 1998 [cited by applicant]
US 6587719B1 · Barrett et al. · 2003 [cited by applicant]
US 6610713B2 · Tracey · 2003 [cited by applicant]
US 6622041B2 · Terry, Jr. et al. · 2003 [cited by applicant]
US 7167750B2 · Knudson et al. · 2007 [cited by applicant]
US 7346395B2 · Lozano et al. · 2008 [cited by applicant]
US 7784583B1 · Hall et al. · 2010 [cited by applicant]
US 7797042B2 · Dietrich et al. · 2010 [cited by applicant]
US 7801601B2 · Maschino et al. · 2010 [cited by applicant]
US 8108047B2 · Schumann · 2012 [cited by applicant]
US 8391970B2 · Tracey et al. · 2013 [cited by applicant]
US 8428719B2 · Napadow · 2013 [cited by applicant]
US 8509905B2 · Alataris et al. · 2013 [cited by applicant]
US 8615309B2 · Craig · 2013 [cited by applicant]
US 8666502B2 · Hartlep et al. · 2014 [cited by applicant]
US 8688239B2 · Hartlep et al. · 2014 [cited by applicant]
US 8729129B2 · Tracey et al. · 2014 [cited by applicant]
US 8774926B2 · Alataris et al. · 2014 [cited by applicant]
US 8843210B2 · Simon et al. · 2014 [cited by applicant]
US 8885861B2 · Beck et al. · 2014 [cited by applicant]
US 8892207B2 · Nelson et al. · 2014 [cited by applicant]
US 8914114B2 · Tracey et al. · 2014 [cited by applicant]
US 8918178B2 · Simon et al. · 2014 [cited by applicant]
US 8983628B2 · Simon et al. · 2015 [cited by applicant]
US 8983629B2 · Simon et al. · 2015 [cited by applicant]
US 9119953B2 · Simon et al. · 2015 [cited by applicant]
US 9179222B2 · Hillbratt et al. · 2015 [cited by applicant]
US 9211409B2 · Tracey et al. · 2015 [cited by applicant]
US 9242085B2 · Hershey et al. · 2016 [cited by applicant]
US 9248286B2 · Simon et al. · 2016 [cited by applicant]
US 9339641B2 · Rajguru et al. · 2016 [cited by applicant]
US 9358381B2 · Simon et al. · 2016 [cited by applicant]
US 9364674B2 · Cook · 2016 [cited by examiner]
US 9399134B2 · Simon et al. · 2016 [cited by applicant]
US 9415220B1 · Spinelli et al. · 2016 [cited by applicant]
US 9662490B2 · Tracey et al. · 2017 [cited by applicant]
US 9861816B2 · Southwell et al. · 2018 [cited by applicant]
US 10010479B2 · Brown et al. · 2018 [cited by applicant]
US 10130809B2 · Cartledge et al. · 2018 [cited by applicant]
US 10258796B2 · Alataris et al. · 2019 [cited by applicant]
US 10493277B2 · Thacker et al. · 2019 [cited by applicant]
US 10603482B2 · Hamner et al. · 2020 [cited by applicant]
US 10603494B2 · Alataris et al. · 2020 [cited by applicant]
US 10625074B2 · Rosenbluth et al. · 2020 [cited by applicant]
US 10765856B2 · Wong et al. · 2020 [cited by applicant]
US 10806928B2 · Sharma et al. · 2020 [cited by applicant]
US 10814130B2 · Wong et al. · 2020 [cited by applicant]
US 10835747B2 · Sharma et al. · 2020 [cited by applicant]
US 10905879B2 · Wong et al. · 2021 [cited by applicant]
US 20020090099A1 · Hwang · 2002 [cited by applicant]
US 20060100672A1 · Litvak · 2006 [cited by applicant]
US 20060122675A1 · Libbus et al. · 2006 [cited by applicant]
US 20060178703A1 · Huston et al. · 2006 [cited by applicant]
US 20070027504A1 · Barrett et al. · 2007 [cited by applicant]
US 20070250145A1 · Kraus et al. · 2007 [cited by applicant]
US 20080021517A1 · Dietrich · 2008 [cited by applicant]
US 20080021520A1 · Dietrich · 2008 [cited by applicant]
US 20080051852A1 · Dietrich et al. · 2008 [cited by applicant]
US 20080082153A1 · Gadsby et al. · 2008 [cited by applicant]
US 20080249594A1 · Dietrich et al. · 2008 [cited by applicant]
US 20090287035A1 · Dietrich et al. · 2009 [cited by applicant]
US 20100057154A1 · Dietrich et al. · 2010 [cited by applicant]
US 20100160996A1 · Simon et al. · 2010 [cited by applicant]
US 20110046432A1 · Simon et al. · 2011 [cited by applicant]
US 20110125203A1 · Simon et al. · 2011 [cited by applicant]
US 20110160811A1 · Walker · 2011 [cited by applicant]
US 20110166624A1 · Dietrich et al. · 2011 [cited by applicant]
US 20110238141A1 · Webb et al. · 2011 [cited by applicant]
US 20110230701A1 · Simon et al. · 2011 [cited by applicant]
US 20110230938A1 · Simon et al. · 2011 [cited by applicant]
US 20110276107A1 · Simon et al. · 2011 [cited by applicant]
US 20110276112A1 · Simon et al. · 2011 [cited by applicant]
US 20120029591A1 · Simon et al. · 2012 [cited by applicant]
US 20120029601A1 · Simon et al. · 2012 [cited by applicant]
US 20130066392A1 · Simon et al. · 2013 [cited by applicant]
US 20130079862A1 · Ellrich · 2013 [cited by applicant]
US 20130131753A1 · Simon et al. · 2013 [cited by applicant]
US 20130184792A1 · Simon et al. · 2013 [cited by applicant]
US 20130245486A1 · Simon et al. · 2013 [cited by applicant]
US 20130253413A1 · Levine et al. · 2013 [cited by applicant]
US 20130310909A1 · Simon et al. · 2013 [cited by applicant]
US 20130317580A1 · Simon et al. · 2013 [cited by applicant]
US 20140046406A1 · Ellrich et al. · 2014 [cited by applicant]
US 20140142654A1 · Simon et al. · 2014 [cited by applicant]
US 20140206945A1 · Liao · 2014 [cited by applicant]
US 20140256592A1 · Faham · 2014 [cited by applicant]
US 20140257438A1 · Simon et al. · 2014 [cited by applicant]
US 20140324118A1 · Simon et al. · 2014 [cited by applicant]
US 20140336730A1 · Simon et al. · 2014 [cited by applicant]
US 20150018925A1 · Zschaeck et al. · 2015 [cited by applicant]
US 20150018926A1 · Frenkel et al. · 2015 [cited by applicant]
US 20150088212A1 · De Ridder · 2015 [cited by applicant]
US 20150088224A1 · Goldwasser et al. · 2015 [cited by applicant]
US 20150112405A1 · Brown et al. · 2015 [cited by applicant]
US 20150142082A1 · Simon et al. · 2015 [cited by applicant]
US 20150165195A1 · Hartlep et al. · 2015 [cited by applicant]
US 20150241447A1 · Zitnik et al. · 2015 [cited by applicant]
US 20150265830A1 · Simon et al. · 2015 [cited by applicant]
US 20150360030A1 · Cartledge et al. · 2015 [cited by applicant]
US 20160022987A1 · Zschaeck et al. · 2016 [cited by applicant]
US 20160050503A1 · Naether · 2016 [cited by applicant]
US 20160096016A1 · Tracey et al. · 2016 [cited by applicant]
US 20160114165A1 · Levine et al. · 2016 [cited by applicant]
US 20160144175A1 · Simon et al. · 2016 [cited by applicant]
US 20160250097A9 · Tracey et al. · 2016 [cited by applicant]
US 20160250464A1 · Zschaeck et al. · 2016 [cited by applicant]
US 20160263376A1 · Yoo et al. · 2016 [cited by applicant]
US 20160279021A1 · Hyde et al. · 2016 [cited by applicant]
US 20160279022A1 · Hyde et al. · 2016 [cited by applicant]
US 20160279023A1 · Hyde et al. · 2016 [cited by applicant]
US 20160279024A1 · Hyde et al. · 2016 [cited by applicant]
US 20160279025A1 · Hyde et al. · 2016 [cited by applicant]
US 20160279435A1 · Hyde et al. · 2016 [cited by applicant]
US 20160310070A1 · Sabesan · 2016 [cited by applicant]
US 20170027812A1 · Hyde et al. · 2017 [cited by applicant]
US 20170043160A1 · Goodall et al. · 2017 [cited by applicant]
US 20170113042A1 · Goodall et al. · 2017 [cited by applicant]
US 20170113057A1 · Goodall et al. · 2017 [cited by applicant]
US 20170203103A1 · Levine et al. · 2017 [cited by applicant]
US 20170296807A1 · Brown et al. · 2017 [cited by applicant]
US 20170368329A1 · Tyler · 2017 [cited by examiner]
US 20180021564A1 · Goodall et al. · 2018 [cited by applicant]
US 20180168905A1 · Goodall et al. · 2018 [cited by applicant]
US 20180169411A1 · Goodall et al. · 2018 [cited by applicant]
US 20180169412A1 · Goodall et al. · 2018 [cited by applicant]
US 20190001129A1 · Rosenbluth et al. · 2019 [cited by applicant]
US 20190046794A1 · Goodall et al. · 2019 [cited by applicant]
US 20200093400A1 · Hamner et al. · 2020 [cited by applicant]
US 20200139126A1 · Napadow · 2020 [cited by examiner]
US 20200094054A1 · Sharma et al. · 2020 [cited by applicant]
US 20200215327A1 · Sharma et al. · 2020 [cited by applicant]
US 20200261722A1 · Alataris · 2020 [cited by examiner]
US 20210085972A1 · Sharma et al. · 2021 [cited by applicant]
AU 2017200484A1 · 2017 [cited by applicant]
EP 2129352B1 · 2016 [cited by applicant]
WO 2010114836A2 · 2010 [cited by applicant]
WO 2016109851A1 · 2016 [cited by applicant]
WO 2017120023A1 · 2017 [cited by applicant]
WO 2018039458A1 · 2018 [cited by applicant]
WO 2018039467A1 · 2018 [cited by applicant]
WO 2019005774A1 · 2019 [cited by applicant]
WO 2019143790A1 · 2019 [cited by applicant]
WO 2020185601A1 · 2020 [cited by applicant]
Wikipedia.org, “Hearing Range,” accessed May 13, 2024, https://en.wikipedia.org/wiki/Hearing_range (Year: 2024). [cited by examiner]
ISA, PCT Application No. PCTUS2019/052699, International Search Report and Written Opinion mailed Dec. 2, 2019, 21 pages. [cited by applicant]
Diener et al., “Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled Premium trial,” Cephalalgia, 39(12): 1475-1487, 2… [cited by applicant]
EPO, Extended European Search Report for European Patent Application 19866172.0, Mail Date: May 16, 2022. 7 pages. [cited by applicant]
Berthoud HR, Neuhuber WL. Functional and chemical anatomy of the afferent vagal system. Auton Neurosci Basic Clin 2000;85:1-17. [cited by applicant]
Evrengül H, Dursunoglu D, Cobankara V, et al. Heart rate variability in patients with rheumatoid arthritis. Rheumatol Int 2004;24:198-202. [cited by applicant]
Fox D. The electric cure. An experimental procedure is exposing the links between the nervous andimmune systems. Could it be the start of a revolution? Nature. 2017;545:20-2. [cited by applicant]
Genovese MC, Gaylis N, Sikes D et al. Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, rando… [cited by applicant]
Koopman FA, Chavan SS, Miljko S et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc Natl Acad Sci 2016;113:8284-9. [cited by applicant]
Koopman FA, van Maanen MA, Vervoordeldonk MJ, et al. Balancing the autonomic nervous system to reduce inflammation in rheumatoid arthritis. J Intern Med Jul. 2017;282:64-75. [cited by applicant]
Van Vollenhoven RF et al. (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 367(6):508-519. [cited by applicant]
Yu et al., “Low-level transcutaneous electrical stimulation of the auricular branch of the vagus nerve: a noninvasive approach to treat the initial phase of atrial fibrillation”, Heart Rhythm, Mar. 2013;10(3):428-35. [cited by applicant]